Astellas Pharma has been granted a patent for a method to acquire and produce high-purity renal progenitor cells for regenerative medicine in renal diseases. The method involves identifying specific cell surface antigen markers and using a combination of cell surface markers for sorting the cell population. Antibodies that bind to the markers are used for selection. GlobalData’s report on Astellas Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Astellas Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Astellas Pharma's grant share as of September 2023 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Method for sorting renal progenitor cells using specific markers
A recently granted patent (Publication Number: US11746332B2) describes an in vitro method for sorting a cell population from a renal progenitor cell-containing cell population. The method involves selecting a specific cell population using a combination of cell surface markers. The patent claims that the selected cell population can be determined by the presence or absence of certain markers, such as CD9, CD140a, CD140b, CD271, CD165, CD106, CD55, and CD326. Antibodies that bind to these markers are used for selecting the cell population.
The patent also mentions that the method can be applied to renal progenitor cells that have been induced to differentiate from pluripotent stem cells. Specifically, induced pluripotent stem (iPS) cells are mentioned as a type of pluripotent stem cells that can be used. The patent further specifies that the pluripotent stem cells can be human iPS cells.
In addition to the method itself, the patent also claims a cell population that is acquired using the described method. This suggests that the method has been successfully used to obtain a specific cell population, which could have potential applications in the field of renal progenitor cell research.
Overall, this granted patent presents a method for sorting a cell population from a renal progenitor cell-containing cell population using a combination of cell surface markers. The method can be applied to renal progenitor cells that have been induced to differentiate from pluripotent stem cells, including human iPS cells. The patent also claims a cell population acquired using this method. This invention could have implications for further research and development in the field of renal progenitor cells and related areas.
To know more about GlobalData’s detailed insights on Astellas Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
